Yang Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yang Zhou has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Miao-Miao Niu
Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, China
4 shared publicationsYuting Wang
Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, China
3 shared publicationsJindong Li
Taizhou School of Clinical Medicine, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou 225300, China
2 shared publications- Yuanqian Qu
Department of Gastroenterology, The First People’s Hospital of Kunshan, Suzhou, China
2 shared publications Chang Su
Department of Pathology, Hangzhou TCM Hospital, Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
1 shared publicationDong Guo
Department of Ultrasound, Hangzhou TCM Hospital, Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 12 September 2026
- Published by Springer Nature in npj Digital Medicine
Deep learning combined habitat radiomics analysis of central lymph node metastasis in papillary thyroid carcinoma
- 12 September 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessDeep learning combined habitat radiomics analysis of central lymph node metastasis in papillary thyroid carcinoma
- 15 May 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 294, 117767
Discovery of a potent and selective peptide inhibitor with d-amino acids targeting the BRD4 ET domain for renal cancer therapy
- 15 May 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 294, 117767
Discovery of a potent and selective peptide inhibitor with d-amino acids targeting the BRD4 ET domain for renal cancer therapy
- 25 February 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 289, 117446
Design, synthesis, and biological evaluation of novel and highly potent peptides targeting syntenin
- 25 February 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 289, 117446
Design, synthesis, and biological evaluation of novel and highly potent peptides targeting syntenin
- 17 April 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (9) , 7130-7145
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer
Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects. Here, we discovered dual SOS1/EGFR-targeting compounds via pharmacophore-based docking screening. The most prominent compound SE-9 exhibited nanomolar inhibition activity against both SOS1 and EGFR and efficiently suppressed the phosphorylation of ERK and AKT in prostate cancer cells PC-3. Cellular assays also revealed that SE-9 displayed strong antiproliferative activities through diverse mechanisms, such as induction of cell apoptosis and G1 phase cell cycle arrest, as well as reduction of angiogenesis and migration. Further in vivo findings showed that SE-9 potently inhibited tumor growth in PC-3 xenografts without obvious toxicity. Overall, SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer.
- 17 April 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (9) , 7130-7145
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer
Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects. Here, we discovered dual SOS1/EGFR-targeting compounds via pharmacophore-based docking screening. The most prominent compound SE-9 exhibited nanomolar inhibition activity against both SOS1 and EGFR and efficiently suppressed the phosphorylation of ERK and AKT in prostate cancer cells PC-3. Cellular assays also revealed that SE-9 displayed strong antiproliferative activities through diverse mechanisms, such as induction of cell apoptosis and G1 phase cell cycle arrest, as well as reduction of angiogenesis and migration. Further in vivo findings showed that SE-9 potently inhibited tumor growth in PC-3 xenografts without obvious toxicity. Overall, SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer.
- Open Access
- 10 July 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1208740
Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity
Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhibition of HDAC1 and SPOP may be a promising strategy for cancer treatment. In this study, we successfully identified four potential dual-targeting HDAC1/SPOP candidate compounds with structure-based virtual screening. In vitro inhibition experiments confirmed that the four compounds had dual inhibitory effects on HDAC1 and SPOP. Among them, compound HS-2 had a stronger inhibitory effect on HDAC1 and SPOP than the positive controls. Further molecular dynamics simulations indicated that HS-2 could stably bind to HDAC1 and SPOP. In addition, MTT assay indicated that HS-2 inhibited the growth of tumor cells in the micromolar range. In vivo evaluation showed that HS-2 could obviously inhibit the growth of tumor in nude mice without obvious toxicity. These findings suggest that HS-2 is a novel and potent dual-targeting HDAC1/SPOP inhibitor for cancer treatment.
- 10 July 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1208740
Open AccessIdentification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity
Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhibition of HDAC1 and SPOP may be a promising strategy for cancer treatment. In this study, we successfully identified four potential dual-targeting HDAC1/SPOP candidate compounds with structure-based virtual screening. In vitro inhibition experiments confirmed that the four compounds had dual inhibitory effects on HDAC1 and SPOP. Among them, compound HS-2 had a stronger inhibitory effect on HDAC1 and SPOP than the positive controls. Further molecular dynamics simulations indicated that HS-2 could stably bind to HDAC1 and SPOP. In addition, MTT assay indicated that HS-2 inhibited the growth of tumor cells in the micromolar range. In vivo evaluation showed that HS-2 could obviously inhibit the growth of tumor in nude mice without obvious toxicity. These findings suggest that HS-2 is a novel and potent dual-targeting HDAC1/SPOP inhibitor for cancer treatment.
- Open Access
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1094887
Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation
KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated that the four compounds had sub-nanomolar affinities for KRASG12D and showed a dose-dependent inhibitory effect on human pancreatic cancer cells. In particular, the hit compound 3 was the most promising candidate and significantly inhibited the tumor growth of pancreatic cancer in tumor-bearing mice. The hit compound 3 represented a promising starting point for structural optimization in hit-to-lead development. This study shows that hit compound 3 provides a basis for the development of the treatment of cancer driven by KRASG12D.
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1094887
Open AccessDiscovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation
KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated that the four compounds had sub-nanomolar affinities for KRASG12D and showed a dose-dependent inhibitory effect on human pancreatic cancer cells. In particular, the hit compound 3 was the most promising candidate and significantly inhibited the tumor growth of pancreatic cancer in tumor-bearing mice. The hit compound 3 represented a promising starting point for structural optimization in hit-to-lead development. This study shows that hit compound 3 provides a basis for the development of the treatment of cancer driven by KRASG12D.